GRISCELLI SYNDROME, TYPE 1
|
0.900 |
Biomarker
|
disease |
MGD |
Mutations of the myosin Va gene cause the neurological diseases Griscelli syndrome type 1 and Elejalde syndrome in humans and dilute phenotypes in rodents.
|
21508232 |
2011 |
GRISCELLI SYNDROME, TYPE 1
|
0.900 |
Biomarker
|
disease |
MGD |
Molecular genetic dissection of mouse unconventional myosin-VA: tail region mutations.
|
9560409 |
1998 |
GRISCELLI SYNDROME, TYPE 1
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene.
|
9207796 |
1997 |
GRISCELLI SYNDROME, TYPE 1
|
0.900 |
GermlineCausalMutation
|
disease |
ORPHANET |
|
|
|
GRISCELLI SYNDROME, TYPE 1
|
0.900 |
Biomarker
|
disease |
CTD_human |
|
|
|
GRISCELLI SYNDROME, TYPE 1
|
0.900 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
GRISCELLI SYNDROME, TYPE 1
|
0.900 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
GRISCELLI SYNDROME, TYPE 3
|
0.500 |
GermlineCausalMutation
|
disease |
ORPHANET |
Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1).
|
12897212 |
2003 |
GRISCELLI SYNDROME, TYPE 3
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity.
|
12148598 |
2002 |
Elejalde Disease
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity.
|
12148598 |
2002 |
GRISCELLI SYNDROME, TYPE 3
|
0.500 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Elejalde Disease
|
0.500 |
GermlineCausalMutation
|
disease |
ORPHANET |
|
|
|
Hypopigmentation-immunodeficiency disease
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Griscelli syndrome (GS), a rare autosomal recessive disorder characterized by partial albinism and immunological impairment and/or severe neurological impairment, results from mutations in the MYO5A (GS1), RAB27A (GS2), or MLPH (GS3) genes.
|
20591709 |
2010 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Griscelli syndrome (GS) is a rare autosomal recessive disorder caused by mutations in either the myosin VA (GS1), RAB27A (GS2) or melanophilin (GS3) genes.
|
19243575 |
2009 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Griscelli syndrome (GS) is a rare autosomal recessive disorder caused by mutation in the MYO5A (GS1, Elejalde), RAB27A (GS2) or MLPH (GS3) genes.
|
19030707 |
2008 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Griscelli syndrome (GS) is caused by mutations in the MYO5A (GS1), RAB27A (GS2), or MLPH (GS3) genes, all of which lead to a similar pigmentary dilution.
|
15163896 |
2004 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1).
|
12897212 |
2003 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
The two patients described elsewhere who have MYO5A mutations and neurological complications but no immunologic defects may not have GS but instead may have Elejalde syndrome, a condition characterized by mild hypopigmentation and severe, primary neurological abnormalities.
|
12058346 |
2002 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
Biomarker
|
disease |
BEFREE |
arg-cys substitution at codon 1246 of the human myosin Va gene is not associated with Griscelli syndrome.
|
10733681 |
2000 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
We previously mapped the disease locus to 15q21 and showed that a MyoVa gene (HGMW-approved symbol MYO5A) defect leads to Griscelli syndrome.
|
10704277 |
2000 |
Hypopigmentation-immunodeficiency disease
|
0.380 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene.
|
9207796 |
1997 |
Peripheral Nervous System Diseases
|
0.310 |
Biomarker
|
group |
BEFREE |
In late-onset bortezomib-induced peripheral neuropathy, the significant genes were SOD2 (upregulated by 1·18 times; p=9·6×10(-3)) and MYO5A (1·93 times; p=3·2×10(-2)), involved in development and function of the nervous system.
|
20864405 |
2010 |
Peripheral Nervous System Diseases
|
0.310 |
Biomarker
|
group |
CTD_human |
In late-onset bortezomib-induced peripheral neuropathy, the significant genes were SOD2 (upregulated by 1·18 times; p=9·6×10(-3)) and MYO5A (1·93 times; p=3·2×10(-2)), involved in development and function of the nervous system.
|
20864405 |
2010 |
Liver Cirrhosis, Experimental
|
0.300 |
Biomarker
|
disease |
CTD_human |
Systems level analysis and identification of pathways and networks associated with liver fibrosis.
|
25380136 |
2014 |
Acrocephalopolydactylous Dysplasia
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|